News Archive

7th July 2016

Aquapharm and AMRI enter into a novel marine chemistry collaboration

Aquapharm Biodiscovery, a leading marine biotechnology company, announced today it has signed a research agreement with Albany Molecular Research (NASDAQ: AMRI) to identify novel drug-like compounds and scaffolds with anti-microbial and anti-inflammatory activity from Aquapharm’s marine natural products library derived from its extensive collection of marine micro-organisms.

28th June 2016

Aquapharm appoints new Chief Scientific Officer

Aquapharm Biodiscovery, a leading marine biotechnology company, announced today the appointment of Dr Tim Morley as Chief Scientific Officer (CSO). Dr Morley’s appointment follows an investment of £4.2 million from existing investors and the appointments of biotech entrepreneur Simon Best as CEO and Aquapharm’s founder Dr Andrew Mearns-Spragg as CTO in March 2016.

23rd March 2016

Aquapharm®completes £4.2 million investment and
appoints Dr Simon Best OBE FRSE as new CEO

Current CEO and founder, Andrew Mearns Spragg, to take position as CTO

Aquapharm Biodiscovery, a leading marine biotechnology company, today announces the close of a £4.2 million investment from existing investors Aescap Venture, Tate & Lyle Ventures, Highlands and Islands Enterprise and NESTA. Alongside the completion of the financing, Aquapharm has appointed the seasoned biotech entrepreneur Simon Best as CEO. Current CEO and founder Andrew Mearns Spragg will take up the role of Chief Technical Officer.MORE>>

1st December 2015

Aquapharm Strengthens Management Team with the Appointment of Research Director

Aquapharm Biodiscovery Ltd, a leading marine biotechnology company, is pleased to announce it has appointed Dr. Lloyd Payne as its Research Director. Lloyd has joined Aquapharm to drive forward the discovery and development of novel bioactives derived from the company's unique collection of marine micro-organisms. MORE>>

1st December 2015

Aquapharm Appoints Business Development Director

Aquapharm Biodiscovery Ltd, a leading marine biotechnology company, is pleased to announce the appointment of Jon Williams as Business Development Director. Jon's primary focus will be to drive forward the commercialisation of scientifically validated, sustainably sourced functional ingredients and industrial biotechnology products derived from Aquapharm's collection of marine micro-organisms. MORE>>

12th March 2015

Aquapharm Strengthens Management Team with Appointment of New Chairman and CFO

Aquapharm Biodiscovery, a leading marine biotechnology company, today announces the appointment of Steve Harris as non-executive Chairman of the board, with immediate effect. Mr. Harris replaces Ron James, the outgoing chairman, who is retiring. The Company also announces the appointment of Sandy McDougall as Chief Financial Officer. MORE>>

4th August 2014

Aquapharm and Croda International Sign Three Year Research Collaboration Agreement

Marine biotechnology company Aquapharm Biodiscovery Ltd and Croda International Plc today announced the signing of a collaboration and license agreement. The three-year collaboration will provide Croda with an exclusive license to novel marine derived natural products identified through the collaboration from strains from Aquapharm's proprietary microbial library for use in topical cosmetic applications in skin and hair care. MORE>>

July 9th 2014

Aquapharm and Dr. Reddy’s Sign Commercial License Agreements

Scottish marine biotechnology company Aquapharm Biodiscovery Limited today announced the signing of a new commercial license agreement and an extension of an existing research and development license agreement with Dr. Reddy’s Laboratories Limited. MORE>>

June 16th 2014

Aquapharm CEO wins Ernst & Young Scottish Entrepreneur of the Year in healthcare

The award recognises Dr Mearns Spragg's entrepreneurial ambition in setting up Aquapharm as well as his pioneering and innovative work in developing new anitbiotic compounds.

May 2014

Aquapharm strengthens board and management team

Mr Douglas Thomson has been appointed as Aquapharm's new Commercial Director and Professor Axel Kleeman has joined the board as a Non-executive Director.

Oct 15th 2013

Founder wins prestigious Gannochy Innovation Award

Dr Andrew Mearns Spragg, founder of Aquapharm has won Scotland's top award for Innovation from the Royal Society of Edinburgh. The Gannochy Innovation Award is an annual award which carries a prize of £50,000 along with a specially commissioned gold medal which will be used to further the development of the company's lead anti-infective candidates.

July 24th 2013

Aquapharm secures second round investment of £4M

Aquapharm's technology has been backed by investments from Aescap Venture, Tate & Lyle Ventures along with further investments by Scottish Enterprise, NESTA and HIE Argyll and the Islands Enterprise.

June 13th 2013

Nexxus

Aquapharm Bio-Discovery wins DTI support to search for anti-cancer agents from its diverse collection of marine microbes.

2013

SIMS Conference

Aquapharm R&D Manager, Dorothee Gotz, is to present at the Society for Industrial Microbiology annual meeting in Denver on the Commercialisation of Extremophiles.

May 6-8th 2013

Aquapharm Exhibits at Vitafoods

In partnership with Scottish Development International (SDI), Aquapharm exhibited at Vitafoods 2013 where significant interest was shown in its carotenoid and nutraceutical based research.

2013

Aquapharm attracts Pharma interest at BIO

Aquapharm CEO, Andrew Mearns Spragg and Business Development Manager, Jason Cleaversmith took part in the bio-partnering events at BIO 2013 in Boston. Significant interest was shown in the developing pipeline of anti-microbial candidates, sourced from marine microbes, and the company now has a number of agreements in place to explore potential partnerships and development programmes for its drug leads.